01 April 2019 | News
Multi-target deal will utilize StrideBio’s platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich’s Ataxia
image credit- diceinsights.com
StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, recently announced the signing of a collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop in vivo AAV based therapies for Friedreich’s Ataxia (FA) and two additional undisclosed targets.
These programmes aim to utilize novel AAV capsids developed by StrideBio to improve potency, evade neutralizing antibodies and enhance specific tropism to tissues including the central nervous system.
Under the terms of the agreement, StrideBio will be responsible for AAV capsid development, non-clinical development and manufacturing of preclinical candidates to be selected for advancement into clinical studies. Takeda will be responsible for clinical development and commercialization of selected candidates arising from the collaboration. A total of three targets are specified under the collaboration, with the initial target being Friedreich’s Ataxia.
StrideBio is eligible to receive approximately $30 million in upfront and near term pre-clinical milestones, as well as an additional $680 million in future development and commercial milestones from Takeda. StrideBio will also receive royalties on worldwide net sales of any commercial products developed through the collaboration. Further financial terms were not disclosed.